X4 Pharmaceuticals Inc (NASDAQ:XFOR)
| 0.74 Delayed Data As of Dec 01 |  -0.04 / -5.13%Today’s Change | 0.65 Today|||52-Week Range 2.58 | -25.48% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $122.7M |
Company Description
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
Contact Information
X4 Pharmaceuticals, Inc. 61 North Beacon Street Boston Massachusetts 02134 |
Employees
Shareholders
| Other institutional | 31.29% |
| Mutual fund holders | 19.34% |
| Individual stakeholders | 1.56% |
Top Executives
| Paula S. Ragan | President, Chief Executive Officer & Director |
| Mary DiBiase | Chief Operating Officer |
| Adam S. Mostafa | Chief Financial Officer, Secretary & Treasurer |
| Art Taveras | Chief Scientific Officer |
| Christophe Arbet-Engels | Chief Medical Officer |
